ClinicalTrials.gg
CompletedNCT02668653QuANTUM-FirstUpdated Aug 6, 2024Results posted

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

A Phase 3 interventional study of Chemotherapy and Quizartinib in Acute Myeloid Leukemia and Leukemia, sponsored by Daiichi Sankyo. Completed at 244 sites in 28 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
539
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.

Enrollment
3rd of 28
539 · median 69
Started
2016
with 3 others
Phase 3
5 of 28
1 open now
Registered
8th of 28
by date
Lead sponsor
10 of 28
Daiichi Sankyo

Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 3rd largest by enrollment, is one of 4 that started in 2016, is one of 5 in phase 3, and was the 8th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About quizartinib

quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing quizartinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.

Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML).

Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.

Read the detailed description

This is a phase 3, randomized, double-blind, placebo-control global study. The purpose of this study is to compare the effect of quizartinib versus placebo (administered with standard induction and consolidation chemotherapy, then administered as continuation therapy for up to 36 cycles) on overall survival in subjects with FLT3-internal tandem duplication (ITD) positive AML.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Leukemia

Keywords

  • Newly diagnosed Acute Myeloid Leukemia
  • FLT3-ITD positive
  • Chemotherapy
  • Induction chemotherapy
  • Consolidation chemotherapy
  • Quizartinib
  • Feline McDonough sarcoma (FMS)-like tyrosine kinase 3
  • AC220
  • FLT3-ITD
  • AML
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be competent and able to comprehend, sign, and date an Ethics Committee (EC) or Institutional Review Board approved Form (ICF) before performance of any study-specific procedures or tests;
  2. Is ≥18 years or the minimum legal adult age (whichever is greater) and ≤75 years (at Screening);
  3. Newly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm, based on the World Health Organization (WHO) 2008 classification (at Screening);
  4. (ECOG) performance status 0-2 (at the time the participant signs their first ICF);
  5. Presence of FLT3-ITD activating mutation in bone marrow (allelic ratio of ≥3% FLT3-ITD/total FLT3);
  6. Participant is receiving standard "7+3" induction chemotherapy regimen as specified in the protocol;
  7. Adequate renal function defined as:

    a. >50 mL/min, as calculated with the modified Cockcroft Gault equation

  8. Adequate hepatic function defined as:

    1. Total serum (TBL) ≤1.5 × (ULN) unless the participant has documented Gilbert's syndrome or the increase is related to increased unconjugated (indirect) bilirubin due to hemolysis;
    2. Serum alkaline phosphatase, (AST) and alanine transaminase (ALT) ≤2.5 × ULN;
  9. Serum electrolytes within normal limits: potassium, calcium (total, or corrected for serum albumin in case of hypoalbuminemia or ionized calcium) and magnesium. If outside of normal limits, participant will be eligible when electrolytes are corrected;
  10. If a woman of , must have a negative serum pregnancy test upon entry into this study and must be willing to use highly effective upon enrollment, during the treatment period and for 6 months following the last dose of drug or cytarabine, whichever is later. A woman is considered of childbearing potential following menarche and until becoming (no menstrual period for a minimum of 12 months);
  11. If male, must be surgically sterile or willing to use highly effective birth control upon enrollment, during the treatment period, and for 6 months following the last dose of investigational drug or cytarabine, whichever is later.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) positive leukemia (ie, chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).
  2. Diagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms;
  3. Prior treatment for AML, except for the following allowances:

    • Leukapheresis;
    • Treatment for hyperleukocytosis with hydroxyurea;
    • Cranial radiotherapy for central nervous system (CNS) leukostasis;
    • Prophylactic intrathecal chemotherapy;
    • Growth factor/cytokine support;
  4. Prior treatment with quizartinib or other FLT3-ITD inhibitors;
  5. Prior treatment with any drug or device within 30 days prior to Randomization (within 2 weeks for investigational or approved immunotherapy) or currently participating in other investigational procedures;
  6. History of known CNS leukemia, including cerebrospinal fluid positive for AML blasts; lumbar puncture is recommended for participants with symptoms of CNS leukemia to rule out extramedullary CNS involvement;
  7. History of other , except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for at least 2 years;
  8. Uncontrolled or significant cardiovascular disease, including any of the following:

    • Bradycardia of less than 50 beats per minute, unless the participant has a pacemaker;
    • Fridericia's Heart Rate Correction Formula () interval >450 msec;
    • Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome);
    • Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg;
    • History of ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes);
    • History of second (Mobitz II) or third degree heart block (participants with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker);
    • History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening;
    • History of Class 3 or 4 heart failure;
    • Known history of (LVEF) ≤45% or less than the institutional lower limit of normal;
    • Complete left bundle branch block;
  9. Active acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy;
  10. Known active clinically relevant liver disease (eg, active , or active );
  11. Known history of (HIV). Participants should be tested for HIV prior to Randomization if required by local regulations or EC;
  12. History of to any in the quizartinib/placebo tablets;
  13. Females who are pregnant or breastfeeding;
  14. Otherwise considered inappropriate for the study by the Investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
539 participants (actual)

Study arms

  • Experimental
    Chemotherapy plus quizartinib

    Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by the experimental drug quizartinib Consolidation: up to 4 cycles of cytarabine followed by the experimental drug quizartinib and/or hematopoeitic stem cell transplant Continuation: up to 36 cycles with the experimental drug quizartinib

    Drug: Chemotherapy · Drug: Quizartinib

  • Active comparator
    Chemotherapy plus placebo

    Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by placebo Consolidation: up to 4 cycles of cytarabine followed by placebo and/or hematopoeitic stem cell transplant Continuation: up to 36 cycles with placebo

    Drug: Chemotherapy · Drug: Placebo

Interventions

  • DrugChemotherapy

    Also known as: Cytarabine, Daunorubicin, Idarubicin

  • Also known as: Test Product

  • DrugPlacebo

    Also known as: Placebo Control

06

What researchers measure

Primary outcomes

  1. Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

    Overall survival is defined as the time from randomization until death from any cause.

    Time frame: Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment

Secondary outcomes

  1. Event-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

    Event-free survival (EFS) is the time from randomization to the earliest date of either refractory disease (or treatment failure \[TF\]), relapse, or death from any cause. Refractory disease is defined as complete remission never achieved during Induction (CR: \>1000 neutrophils, \>100,000 platelets, \<5% blasts, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\]). For refractory disease, EFS event date is Day 1 (randomization). Relapse after CR is defined as ≥5% blasts, leukemic blasts, extramedullary leukemia, and presence of rods. This analysis is based on a response assessment with TF defined as not achieving response of CR, using a 42- day window from the start of the last cycle in Induction for CR evaluation.

    Time frame: Date of randomization to the date of refractory disease, relapse, or death, up to approximately 3 years after enrollment

  2. Complete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

    Complete remission (CR) rate is defined as the percentage of participants achieving CR, defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], after induction

    Time frame: Approximately Cycle 1 Day 21 (Induction) to end of Induction, up to approximately 120 days (each Induction cycle is up to 60 days)

  3. Composite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

    Composite complete remission (CRc) rate is defined as the percentage of participants whose best response is complete remission (CR), defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], or CR with incomplete neutrophil or platelet recovery (CRi) at the end of first Induction cycle.

    Time frame: Approximately Cycle 1 Day 21 (Induction) to end of Induction, up to approximately 120 days (each Induction cycle is up to 60 days)

  4. Number of Participants With Treatment-emergent Adverse Events Occurring in ≥10% Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

    A treatment-emergent adverse event (TEAE) is defined as an adverse event that occur, having been absent before first dose of quizartinib or placebo, or have worsened in severity after initiating quizartinib or placebo. Adverse events collected more than 30 days after the last dose of quizartinib/placebo will not be considered TEAEs unless they are considered drug-related.

    Time frame: Date of first dose up to 30 days after last dose, up to 36 cycles following continuation (approximately 6 years 11 months, each cycle is 28 days)

  5. Number of Participants Achieving CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

    Complete remission (CR) is defined as participants achieving CR defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\]. Minimal or measurable residual disease is the presence of a small number of leukemic cells in the bone marrow of patients with AML below the level of detection using conventional morphologic assessment.

    Time frame: Approximately Cycle 1 Day 21 (Induction phase) to end of Induction phase, up to approximately 120 days (each Induction cycle is up to 60 days)

  6. Number of Participants Achieving Composite CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

    Composite complete remission (CRc) is defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], or CR with incomplete neutrophil or platelet recovery (CRi). Minimal or measurable residual disease is the presence of a small number of leukemic cells in the bone marrow of patients with AML below the level of detection using conventional morphologic assessment.

    Time frame: Approximately Cycle 1 Day 21 (Induction phase) to end of Induction phase, up to approximately 120 days (each Induction cycle is up to 60 days)

  7. Pharmacokinetic Parameter Area Under the Concentration Versus Time Curve at Steady State

    AUCss was assessed by population Pharmacokinetic (PK) analysis during Cycle 1 of each phase.

    Time frame: Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)

  8. Pharmacokinetic Parameter Steady State, Maximum Plasma Concentration (Css,Max)

    Css,max was assessed by population PK analysis during Cycle 1 of each phase.

    Time frame: Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)

  9. Pharmacokinetic Parameter Time to Maximum Plasma Concentration Steady State (Tmax,ss)

    Tmax,ss was assessed by population PK analysis during Cycle 1 of each phase.

    Time frame: Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)

07

Results

Posted Oct 5, 2022

Participant flow

A total of 539 participants who met all inclusion criteria and no exclusion criteria were randomized to treatment at 193 study sites in the following countries: Spain, Italy, Republic of Korea, Japan, China, US, France, Brazil, Germany, Russian Federation, Taiwan, Hungary, Czech Republic, Romania, Israel, Canada, Serbia, Poland, Portugal, Australia, Belgium, Bulgaria, Croatia, Ukraine, Singapore, and the UK. A total of 6 participants were randomized, but did not received treatment.

Participant flow — Overall Study
MilestoneQuizartinibPlacebo
Started268271
Safety analysis set265268
Completed5652
Not completed212219
Withdrew: Refractory disease4170
Withdrew: Relapse4465
Withdrew: Adverse event5823
Withdrew: Subject decision to stop study drug2523
Withdrew: Other reasons not specified1611
Withdrew: Non-protocol-specified aml therapy126
Withdrew: Investigator decision107
Withdrew: Failure to meet continuation criteria512
Withdrew: Lost to follow-up10
Withdrew: Pregnancy01
Withdrew: Death01

Outcome measures

PrimaryOverall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

Overall survival is defined as the time from randomization until death from any cause.

Time frame:
Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment
Reported as:
Median · months
Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
monthsQuizartinibPlacebo
Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia31.9 (21.0 to NA)15.1 (13.2 to 26.2)
Statistical analysis
  • Quizartinib vs Placebo · Log Rank · p = 0.0324 · Hazard ratio (hr): 0.776 · 95% CI 0.615 to 0.979Stratification factors include region, age, and WBC count at the time of diagnosis of AML.
SecondaryEvent-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

Event-free survival (EFS) is the time from randomization to the earliest date of either refractory disease (or treatment failure \[TF\]), relapse, or death from any cause. Refractory disease is defined as complete remission never achieved during Induction (CR: \>1000 neutrophils, \>100,000 platelets, \<5% blasts, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\]). For refractory disease, EFS event date is Day 1 (randomization). Relapse after CR is defined as ≥5% blasts, leukemic blasts, extramedullary leukemia, and presence of rods. This analysis is based on a response assessment with TF defined as not achieving response of CR, using a 42- day window from the start of the last cycle in Induction for CR evaluation.

Time frame:
Date of randomization to the date of refractory disease, relapse, or death, up to approximately 3 years after enrollment
Reported as:
Median · months
Event-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
monthsQuizartinibPlacebo
Event-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia0.03 (0.03 to 0.95)0.71 (0.03 to 3.42)
SecondaryComplete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

Complete remission (CR) rate is defined as the percentage of participants achieving CR, defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], after induction

Time frame:
Approximately Cycle 1 Day 21 (Induction) to end of Induction, up to approximately 120 days (each Induction cycle is up to 60 days)
Reported as:
Count of participants · Participants
Complete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
ParticipantsQuizartinibPlacebo
Complete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia147150
SecondaryComposite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

Composite complete remission (CRc) rate is defined as the percentage of participants whose best response is complete remission (CR), defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], or CR with incomplete neutrophil or platelet recovery (CRi) at the end of first Induction cycle.

Time frame:
Approximately Cycle 1 Day 21 (Induction) to end of Induction, up to approximately 120 days (each Induction cycle is up to 60 days)
Reported as:
Count of participants · Participants
Composite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
ParticipantsQuizartinibPlacebo
Composite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia192176
SecondaryNumber of Participants With Treatment-emergent Adverse Events Occurring in ≥10% Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

A treatment-emergent adverse event (TEAE) is defined as an adverse event that occur, having been absent before first dose of quizartinib or placebo, or have worsened in severity after initiating quizartinib or placebo. Adverse events collected more than 30 days after the last dose of quizartinib/placebo will not be considered TEAEs unless they are considered drug-related.

Time frame:
Date of first dose up to 30 days after last dose, up to 36 cycles following continuation (approximately 6 years 11 months, each cycle is 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events Occurring in ≥10% Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
ParticipantsQuizartinibPlacebo
Any TEAE264265
Gastrointestinal disorders215209
Diarrhoea9894
Nausea9084
Vomiting6553
Stomatitis5756
Constipation5669
Abdominal pain4638
Dyspepsia3023
Abdominal pain upper2925
Infections and infestations204188
Pneumonia3941
Sepsis1528
General disorders and administration site disorders177173
Pyrexia112109
Oedema peripheral3037
Fatigue2923
Blood and lymphatic system disorders168143
Febrile neutropenia117113
Neutropenia5427
Thrombocytopenia3030
Anaemia2919
Metabolism and nutrition disorders165153
Hypokalaemia9396
Decreased appetite4636
Hypomagnesaemia3030
Hypophosphataemia2724
Hypocalcaemia2629
Skin and subcutaneous tissue disorders152158
Rash6966
Pruritus3540
Investigations140105
Alanine aminotransferase increased4227
Electrocardiogram QT prolonged3611
Aspartate aminotransferase increased2819
Neutrophil count decreased2712
Respiratory, thoracic, and mediastinal disorders123115
Cough5044
Epistaxis4029
Oropharyngeal pain2718
Nervous system disorders10397
Headache7353
Musculoskeletal and connective tissue disorders91108
Arthralgia2935
Back pain1928
Vascular disorders7170
Hypertension2933
Psychiatric disorders5750
Insomnia3730
SecondaryNumber of Participants Achieving CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

Complete remission (CR) is defined as participants achieving CR defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\]. Minimal or measurable residual disease is the presence of a small number of leukemic cells in the bone marrow of patients with AML below the level of detection using conventional morphologic assessment.

Time frame:
Approximately Cycle 1 Day 21 (Induction phase) to end of Induction phase, up to approximately 120 days (each Induction cycle is up to 60 days)
Reported as:
Count of participants · Participants
Number of Participants Achieving CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
ParticipantsQuizartinibPlacebo
Number of Participants Achieving CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia5451
SecondaryNumber of Participants Achieving Composite CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

Composite complete remission (CRc) is defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], or CR with incomplete neutrophil or platelet recovery (CRi). Minimal or measurable residual disease is the presence of a small number of leukemic cells in the bone marrow of patients with AML below the level of detection using conventional morphologic assessment.

Time frame:
Approximately Cycle 1 Day 21 (Induction phase) to end of Induction phase, up to approximately 120 days (each Induction cycle is up to 60 days)
Reported as:
Count of participants · Participants
Number of Participants Achieving Composite CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
ParticipantsQuizartinibPlacebo
Number of Participants Achieving Composite CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia6658
SecondaryPharmacokinetic Parameter Area Under the Concentration Versus Time Curve at Steady State

AUCss was assessed by population Pharmacokinetic (PK) analysis during Cycle 1 of each phase.

Time frame:
Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Pharmacokinetic Parameter Area Under the Concentration Versus Time Curve at Steady State
nanogram/milliliter (ng/mL)Quizartinib
Induction Period2680 ± 84.9
Consolidation Period3930 ± 77.6
Continuation Period - Dose 15080 ± 74.7
Continuation Period - Dose 210200 ± 74.7
SecondaryPharmacokinetic Parameter Steady State, Maximum Plasma Concentration (Css,Max)

Css,max was assessed by population PK analysis during Cycle 1 of each phase.

Time frame:
Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Pharmacokinetic Parameter Steady State, Maximum Plasma Concentration (Css,Max)
nanogram/milliliter (ng/mL)Quizartinib
Induction Period140 ± 71.2
Consolidation Period204 ± 63.5
Continuation Period - Dose 1265 ± 59.7
Continuation Period - Dose 2529 ± 59.7
SecondaryPharmacokinetic Parameter Time to Maximum Plasma Concentration Steady State (Tmax,ss)

Tmax,ss was assessed by population PK analysis during Cycle 1 of each phase.

Time frame:
Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)
Reported as:
Median · hours
Pharmacokinetic Parameter Time to Maximum Plasma Concentration Steady State (Tmax,ss)
hoursQuizartinib
Induction Period2.68 (1.52 to 7.30)
Consolidation Period2.70 (1.74 to 5.95)
Continuation Period - Dose 12.73 (1.74 to 5.95)
Continuation Period - Dose 22.73 (1.74 to 5.95)

Adverse events

Collected over Treatment-emergent adverse events were collected from date of first dose up to 30 days after last dose, up to 36 cycles following continuation phase (approximately 6 years 11 months, each cycle is 28 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Quizartinib130/265 (49.1%)146/265 (55.1%)258/265 (97.4%)
Placebo156/268 (58.2%)124/268 (46.3%)258/268 (96.3%)
Most frequent serious events
Showing 10 of 222
Most frequent serious events
EventQuizartinibPlacebo
Febrile neutropeniaBlood and lymphatic system disorders29/26522/268
PneumoniaInfections and infestations17/26515/268
SepsisInfections and infestations10/26514/268
Septic shockInfections and infestations11/2659/268
PyrexiaGeneral disorders8/2655/268
ThrombocytopeniaBlood and lymphatic system disorders2/2658/268
Klebsiella sepsisInfections and infestations7/2651/268
Herpes zosterInfections and infestations5/2651/268
NeutropeniaBlood and lymphatic system disorders4/2655/268
Anal fistulaGastrointestinal disorders4/2650/268
Most frequent other events
Showing 10 of 63
Most frequent other events
EventQuizartinibPlacebo
PyrexiaGeneral disorders113/265106/268
Febrile neutropeniaBlood and lymphatic system disorders98/26597/268
DiarrhoeaGastrointestinal disorders97/26594/268
HypokalaemiaMetabolism and nutrition disorders93/26596/268
NauseaGastrointestinal disorders91/26584/268
HeadacheNervous system disorders73/26554/268
RashSkin and subcutaneous tissue disorders69/26566/268
ConstipationGastrointestinal disorders57/26569/268
VomitingGastrointestinal disorders63/26551/268
StomatitisGastrointestinal disorders56/26555/268

Baseline characteristics

Demographic and baseline characteristics were assessed in the Intent-to-Treat Analysis Set.

Age, Continuous
Age, Continuous(years)QuizartinibPlaceboTotal
Mean53.6 ± 13.0754.3 ± 12.8154.0 ± 12.93
Age, Customized
Age, Customized(Participants)QuizartinibPlaceboTotal
<60 years161162323
≥60 years107109216
Sex: Female, Male
Sex: Female, Male(Participants)QuizartinibPlaceboTotal
Female144150294
Male124121245
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)QuizartinibPlaceboTotal
American Indian or Alaska Native011
Asian8078158
Native Hawaiian or Other Pacific Islander000
Black or African American257
White159163322
Other272451
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)QuizartinibPlaceboTotal
Singapore628
United States81321
Czechia171532
Portugal369
Russia13619
South Korea363470
China91120
Brazil7815
Poland3811
Bulgaria112
France131225
Serbia12618
Croatia51015
Romania61117
Hungary459
Japan161329
Ukraine213
United Kingdom101
Spain333467
Canada8513
Belgium437
Taiwan121729
Italy312960
Israel5914
Australia358
Germany10717
08

Study locations

244 sites
  • University of Florida (UF) Health Shands Hospital
    Gainesville, Florida 90095, United States
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Franciscan St. Francis Health Indianapolis
    Indianapolis, Indiana 46237, United States
  • University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • NY Medical College - Hudson Valley Hematology Oncology Associates
    Valhalla, New York 10595, United States
  • Duke Clinical Research Institute
    Durham, North Carolina 27710, United States
  • University Hospitals Seidman Cancer Center
    Cleveland, Ohio 44106, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • West Virginia University Hospitals, Inc.
    Morgantown, West Virginia 26506, United States
  • Sanatorio Britanico
    Rosario, Santa Fe S2000CVB, Argentina
  • Sanatorio Allende
    Córdoba, X5000JHQ, Argentina
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Townsville Hospital (TTH)
    Douglas, Queensland 4814, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • AZ Sint-Jan Brugge-Oostende AV
    Brugge, 8000, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • UCL Mont-Godinne
    Yvoir, 5530, Belgium
  • Hospital Amaral Carvalho
    Brasília, 70750-521, Brazil
  • Hospital do CEPON
    Brasília, 70750-521, Brazil
  • Instituto do Cancer do Estado de São Paulo
    Brasília, 70750-521, Brazil
  • Santa Casa de Misericórdia de Porto Alegre
    Brasília, 70750-521, Brazil
  • Hospital da Cidade de Passo Fundo
    Passo Fundo, 99010-260, Brazil
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, 90035-903, Brazil
  • University Multiprofile Hospital for Active Treatment "Dr. G. Stranski" EAD
    Pleven, 5800, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD
    Sofia, 1000, Bulgaria
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G-3G3, Canada
  • Vancouver General Hospital (VGH)
    Vancouver, British Columbia V5Z 1M9, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 1X5, Canada
  • Peking University First Hospital
    Beijing, 100034, China
  • The General Hospital of People's Liberation Army (301 Hospital)
    Beijing, 100853, China
  • Fujian Medical University Union Hospital
    Fuzhou, 350001, China
  • Guangdong General Hospital
    Guangzhou, 510030, China
  • Lanzhou University Second Hospital
    Lanzhou, 730030, China
  • Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School
    Shanghai, 200025, China
  • West China Hospital, Sichuan University
    Taiyuan, 30001, China
  • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
    Tianjin, 300020, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, 325015, China
  • Tang Du Hospital, Fourth Military Medical University
    Xi'an, 710038, China
  • Henan Cancer Hospital
    Zhengzhou, 450008, China
  • Klinička Bolnica Dubrava
    Zagreb, 10000, Croatia
  • Klinička Bolnica Merkur
    Zagreb, 10000, Croatia
  • Klinički Bolnički Centar Zagreb
    Zagreb, 10000, Croatia
  • Fakultní Nemocnice Hradec Králové
    Hradec Kralove, 500 05, Czechia
  • Fakultní Nemocnice Olomouc
    Olomouc, 775 20, Czechia
  • Fakultní Nemocnice Ostrava
    Ostrava, 708 52, Czechia
  • Fakultni Nemocnice Plzen
    Plzen, 304 60, Czechia
  • Vseobecna Fakultni Nemocnice, Ustav hematologie a krevni transfuze (UHKT)
    Praha 2, 128 20, Czechia
  • Hospital A. Michallon
    Grenoble, 38043, France
  • Centre Hospitalier de Versailles - Hôpital André Mignot
    Le Chesnay, 78150, France
  • Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez
    Lille, 59037, France
  • Centre Léon Bérard
    Lyon, 69373, France
  • L'Institut Paoli - Calmettes
    Marguerittes, 13009, France
  • Hôpital de la Conception
    Marseille, 13385, France
  • CHRU Montpellier - Saint Eloi
    Montpellier, 34295, France
  • Hôpital Saint-Antoine
    Paris, 75012, France
  • Hôpital Saint-Louis
    Paris, 75475, France
  • Hôpital Haut-Lévêque
    Pessac, 33604, France
  • Centre Hospitalier Lyon-Sud
    Pierre Benite, 69495, France
  • Centre Henri Becquerel - Centre de Lutte Contre le Cancer
    Rouen, 76038, France
  • Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan
    Toulouse, 31059, France
  • HELIOS Klinikum Bad Saarow
    Bad Saarow, 15526, Germany
  • Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Städtisches Klinikum Braunschweig gGmbH
    Braunschweig, 38114, Germany
  • Marien Hospital Düsseldorf GmbH
    Düsseldorf, 40479, Germany
  • Universitätsklinikum Essen
    Essen, 45122, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt am Main, 60590, Germany
  • Universitätsklinikum Halle (Saale)
    Halle, 6120, Germany
  • Evangelisches Krankenhaus Hamm gGmbH
    Hamm, 59063, Germany
  • Medizinische Hochschule Hannover (MHH)
    Hannöver, 30625, Germany
  • Universitätsklinikum Münster
    Heidelberg, 69115, Germany
  • Universitätsklinikum Tübingen
    Heidelberg, 69115, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Universitätsklinikum Leipzig
    Leipzig, 4103, Germany
  • Stauferklinikum Schwäbisch Gmünd
    Mutlangen, 73557, Germany
  • HELIOS Klinikum Wuppertal
    Wuppertal, 42283, Germany
  • Prince of Wales Hospital
    Shatin, Hong Kong
  • Markusovszky Egyetemi Oktatókórház
    Budapest, 1051, Hungary
  • Szegedi Tudományegyetem
    Budapest, 1051, Hungary
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Debreceni Egyetem Klinikai Központ
    Debrecen, 4032, Hungary
  • Pecsi Tudomanyegyetem Klinikai Központ
    Pécs, 7624, Hungary
  • Markusovszky Egyetemi Oktatókórház
    Szombathely, 9700, Hungary
  • Assaf Harofeh Medical Center
    Be'er Ya'aqov, Tsifrin 70300, Israel
  • Bnai Zion Medical Center
    Haifa, 31048, Israel
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Hadassah University Medical Center
    Jerusalem, 91120, Israel
  • Rabin Medical Center - Beilinson Hospital
    Petaẖ Tiqwa, 49100, Israel
  • The Chaim Sheba Medical Center
    Ramat-Gan, 52621, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Azienda Ospedaliera Nazionale SS.Antonio e Biagio e Cesare Arrigo
    Alessandria, 15121, Italy
  • Azienda Sanitaria Locale 13 - Ospedale "C. e G. Mazzoni"- Ascoli Piceno
    Ascoli Piceno, 63100, Italy
  • Azienda Ospedaliero - Universitaria Consorziale Policlinico di Bari
    Bari, 70124, Italy
  • Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
    Bologna, 40138, Italy
  • IRCCS AOU San Martino - IST
    Genova, 16132, Italy
  • ASST Grande Ospedale Metropolitano Niguarda
    Milano, 20162, Italy
  • A.O.R.N. "A. Cardarelli"
    Napoli, 80131, Italy

Showing the first 100 of 244 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cortes J, Perl AE, Dohner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Kramer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31. PubMed 29859851 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Aug 2021, 59 months.

Results were first posted in Oct 2022, 1 year 1 month after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 59 months is above that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2016
First posted
Jan 29, 2016
StartActual
Sep 1, 2016
Primary completionActual
Aug 13, 2021
CompletionActual
Jun 16, 2023
Results first posted
Oct 5, 2022
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02668653
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jan 29, 2016
Start date
Sep 1, 2016
Primary completion
Aug 13, 2021
Completion
Jun 16, 2023
Results posted
Oct 5, 2022
Last update
Aug 6, 2024

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Quizartinib

Start the discussion